Free Trial

AbbVie (ABBV) Stock Forecast & Price Target

$194.67
+1.66 (+0.86%)
(As of 10/9/2024 ET)

AbbVie - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
14

Based on 16 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for ABBV.

Consensus Price Target

$197.67
1.54% Upside
According to the 16 analysts' twelve-month price targets for AbbVie, the average price target is $197.67. The highest price target for ABBV is $225.00, while the lowest price target for ABBV is $150.00. The average price target represents a forecasted upside of 1.54% from the current price of $194.67.
Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

Sign Up

ABBV Analyst Ratings Over Time

TypeCurrent Forecast
10/10/23 to 10/9/24
1 Month Ago
9/10/23 to 9/9/24
3 Months Ago
7/12/23 to 7/11/24
1 Year Ago
10/10/22 to 10/10/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
8 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$197.67$191.64$181.07$166.53
Forecasted Upside1.54% Upside-2.41% Downside6.56% Upside11.84% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbbVie Stock vs. The Competition

TypeAbbVieMedical CompaniesS&P 500
Consensus Rating Score
2.94
2.79
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside0.09% Upside11,088.45% Upside7.37% Upside
News Sentiment Rating
Neutral News

See Recent ABBV News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/9/2024UBS Group
4 of 5 stars
 Boost TargetNeutral ➝ Neutral$185.00 ➝ $195.00+0.17%
10/7/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$200.00 ➝ $212.00+9.75%
10/7/2024TD Cowen
4 of 5 stars
 Boost TargetBuy ➝ Buy$195.00 ➝ $225.00+16.22%
8/30/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/23/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$196.00 ➝ $209.00+6.05%
8/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$211.00 ➝ $218.00+14.81%
8/5/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00+8.40%
7/26/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$200.00 ➝ $205.00+12.53%
7/26/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$195.00 ➝ $210.00+15.28%
7/19/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$180.00 ➝ $214.00+24.50%
7/3/2024Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$190.00 ➝ $190.00+14.48%
6/5/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$185.00+14.08%
3/22/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$188.00 ➝ $190.00+6.41%
2/5/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$181.00 ➝ $189.00+12.05%
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$173.00+15.89%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$150.00+5.60%
7/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$170.00 ➝ $160.00+18.02%
4/5/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/22/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
2/10/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$157.00 ➝ $154.00+1.83%
2/10/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%
2/10/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%
11/8/2022Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$155.00 ➝ $140.00-7.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:10 PM ET.


Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 6, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

AbbVie
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie offers a competitive dividend yield of 3.24%, providing investors with a steady income stream.
  • The company has a diverse portfolio of pharmaceutical products, including Humira, Skyrizi, and Rinvoq, catering to various medical conditions and diseases.
  • Recent analyst ratings have been overwhelmingly positive, with an average target price of $191.64, indicating strong growth potential.
  • AbbVie's stock price has shown resilience, trading at $191.16, near its 1-year high of $199.95, reflecting investor confidence.
  • With a strong buy rating from William Blair and an outperform rating from BMO Capital Markets, AbbVie is well-positioned for future growth.

AbbVie
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AbbVie for these reasons:

  • AbbVie's dividend payout ratio is currently high at 183.98%, indicating that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment for growth.
  • Chairman Richard A. Gonzalez has been actively selling AbbVie shares, raising concerns about insider sentiment and future performance.
  • The stock's price-to-earnings ratio of 57.04 and a PEG ratio of 2.65 suggest that the stock may be overvalued compared to industry peers.
  • While AbbVie has a strong product pipeline, there may be regulatory risks associated with drug approvals and patent expirations in the pharmaceutical industry.
  • AbbVie's beta of 0.64 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors seeking higher returns.

ABBV Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $197.67, with a high forecast of $225.00 and a low forecast of $150.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.

According to analysts, AbbVie's stock has a predicted upside of 1.54% based on their 12-month stock forecasts.

Over the previous 90 days, AbbVie's stock had 1 upgrade by analysts.

Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.94 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ABBV compares to other companies.


This page (NYSE:ABBV) was last updated on 10/9/2024 by MarketBeat.com Staff
From Our Partners